Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform, connecting users with licensed healthcare professionals in the U.S. and the U.K. [3] Allegations and Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Hims, stemming from allegations of providing potentially misleading business information to the investing public [1] - On April 29, 2025, Novo Nordisk announced it would sell its weight loss drug Wegovy through Hims' telehealth platform, but on June 23, 2025, Novo Nordisk terminated its partnership with Hims due to concerns about Hims' compliance with laws governing the sale and marketing of compounded drugs [4] - Following the termination of the partnership, Hims' stock price fell by $22.24 per share, or 34.63%, closing at $41.98 per share on June 23, 2025 [4]

SAN DIEGO, July 1, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ; SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit.  Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sarepta' ...

NEW YORK, July 1, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) and certain of its officers.Class DefinitionThis lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sarepta ...

LOS ANGELES, July 01, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR ROCKET INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CL ...

Core Viewpoint - 3D Systems Corporation is facing a class action lawsuit due to significant financial losses and misleading statements made by the company regarding its business performance and outlook during the Class Period from August 13, 2024, to May 12, 2025 [1][5]. Financial Performance - On March 26, 2025, 3D Systems reported its Q4 and full-year 2024 results, missing consensus estimates for non-GAAP earnings-per-share and sales revenue, attributing the shortfall to lower hardware systems sales caused by macroeconomic factors [2]. - The company experienced a revenue reduction of $9 million in Q4 due to changes in accounting estimates related to its Regenerative Medicine program [2]. - Following this announcement, the stock price dropped by $0.57, or 21%, closing at $2.15 per share on March 27, 2025 [2]. - On May 12, 2025, 3D Systems released its Q1 2025 results, again missing estimates, primarily due to a decline in material sales linked to inventory management issues in its Healthcare Solutions segment [3]. - The company withdrew its full-year 2025 outlook, citing ongoing softness in customer capital spending and macroeconomic uncertainty [3]. - The stock price fell further by $0.68, or 26.6%, closing at $1.87 per share on May 13, 2025 [4]. Lawsuit Details - The class action lawsuit alleges that 3D Systems made materially false and misleading statements and failed to disclose adverse facts about its business and prospects during the Class Period [5]. - Specific allegations include the understatement of the impact of weakened customer spending and the overstatement of the company's resilience in challenging conditions [5]. - The lawsuit claims that the updated milestone criteria in the United Partnership negatively affected the revenue from the Regenerative Medicine Program [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in its stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Company Actions and Events - On April 29, 2025, Hims announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy on its platform [2]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims, citing deceptive promotion and safety risks associated with Hims' products [2]. - Following the termination announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Hims made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include Hims' engagement in deceptive practices regarding the sale of knockoff Wegovy versions and the risk of partnership termination with Novo Nordisk [3]. - The lawsuit claims that Hims' positive statements about its business lacked a reasonable basis due to these undisclosed risks [3].

Core Viewpoint - Block & Leviton is investigating PetMed Express, Inc. for potential securities law violations following a delayed 10-K filing and internal investigations into revenue recognition [2][4]. Group 1: Investigation Details - The investigation is prompted by concerns related to a Q4 promotional campaign and internal accounting controls [2]. - Block & Leviton may file an action to recover losses on behalf of investors who have lost money in PetMed Express [4]. Group 2: Eligibility and Contact Information - Any investor who purchased PetMed Express common stock and experienced a decline in share value may be eligible to participate in the investigation [3]. - Investors are encouraged to contact Block & Leviton for more information via their case website, email, or phone [5]. Group 3: Whistleblower Information - Individuals with non-public information about PetMed Express are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

You have until August 25, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Hims & Hers securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. [Click here for information about joining the class action] On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled o ...

[Click here for information about joining the class action] On May 8, 2025, after the market closed, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of $49.3 million, a significant decline from the prior quarter's $73.7 million. The Company also announced its full fiscal year 2025 total product revenue guidance had been slashed from $450 million - $475 million to $250 million - $300 million, a reduction of over 40% at the midpoint. Iovance revealed it w ...

Core Viewpoint - A class action securities lawsuit has been filed against Bitfarms Ltd. alleging securities fraud that affected investors between March 21, 2023, and December 9, 2024 [1]. Group 1: Allegations of Fraud - The lawsuit claims that Bitfarms had inadequate internal controls over financial reporting [2]. - It is alleged that the company misclassified proceeds from the sale of digital assets, categorizing them as cash flow from operating activities instead of investing activities [2]. - The complaint states that Bitfarms overstated its remediation efforts regarding material weaknesses in its internal controls related to the classification of 2021 Warrants [2]. - These errors purportedly led to misstatements in several of the company's previously issued financial statements, which may need to be restated [2]. - As a result, the public statements made by the company were deemed materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Bitfarms Ltd. during the specified timeframe have until July 8, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].